Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection

Liver International

Volumn 29, Issue 7, 2009, Pages 1051-1055

  Alvarez Uria, Gerardo ^a,b   Day, Jeremy N ^a,c   Nasir, Anisa J ^a   Russell, Susan K ^a   Vilar, Francisco Javier ^a  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c The Hospital for Tropical Diseases   (Viet Nam)

Author keywords

Antidepressive agents; Depression; Liver cirrhosis; Peginterferon; Psychotic disorders

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PSYCHOSIS; RELAPSE; RISK FACTOR; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; COHORT STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MENTAL DISORDERS; MIDDLE AGED; ODDS RATIO; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT FAILURE; VIRAL LOAD;

EID: 67650480397     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01958.x     Document Type: Article

References (28)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
2. Batista-Neves SC, Quarantini LC, de Almeida AG, et al. High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry 2008; 30: 80-2.
3. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813-20.
4. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
5. Lacey C, Ellen S, Devlin H, Wright E, Mijch A. Hepatitis C in psychiatry inpatients: Testing rates, prevalence and risk behaviours. Australas Psychiatry 2007; 15: 315-9.
6. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
7. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-92.
8. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001; 94: 153-8.
9. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl. 5): S325-9.
10. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
11. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: A randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
12. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C - a pilot study. Dig Dis Sci 2007; 52: 2557-63.
13. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.
14. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-8.
15. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007; 46: 991-8.
16. Bozikas V, Petrikis P, Balla A, Karavatos A. An interferon-alpha-induced psychotic disorder in a patient with chronic hepatitis C. Eur Psychiatry 2001; 16: 136-7.
17. Quarantini LC, Cruz SC, Batista-Neves SC, et al. Psychosis during peginterferon-alpha2a and ribavirin therapy: Case report. Braz J Infect Dis 2006; 10: 406-7.
18. Sockalingam S, Balderson K. Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment. Int Clin Psychopharmacol 2005; 20: 289-90.
19. Telio D, Sockalingam S, Stergiopoulos V. Persistent psychosis after treatment with interferon alpha: A case report. J Clin Psychopharmacol 2006; 26: 446-7.
20. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry 2003; 18: 142-3.
21. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006; 26: 655-62.
22. Van Thiel DH, Friedlander L, Molloy PJ, et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7: 165-8.
23. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007; 102: 2426-33.
24. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
25. Robaeys G, Van VH, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18: 159-66.
26. Seal KH, Currie SL, Shen H, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter? J Clin Gastroenterol 2007; 41: 199-205.
27. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(Suppl. 5): S336-8.
28. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-43.